Omeros Corp.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Omeros Corp.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Omeros Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Omeros Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Omeros Corp. is OMER:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Omeros Corp. has its primary listing on NASDAQ. You can trade Omeros Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Omeros Corp. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Omeros Corp. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Omeros Corp..